These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 7686815)
1. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Yanuck M; Carbone DP; Pendleton CD; Tsukui T; Winter SF; Minna JD; Berzofsky JA Cancer Res; 1993 Jul; 53(14):3257-61. PubMed ID: 7686815 [TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides. Bertholet S; Iggo R; Corradin G Eur J Immunol; 1997 Mar; 27(3):798-801. PubMed ID: 9079825 [TBL] [Abstract][Full Text] [Related]
3. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315 [TBL] [Abstract][Full Text] [Related]
4. Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes. Ciernik IF; Berzofsky JA; Carbone DP Clin Cancer Res; 1996 May; 2(5):877-82. PubMed ID: 9816244 [TBL] [Abstract][Full Text] [Related]
6. Induction of CTL in vivo by major histocompatibility complex class I-peptide complexes covalently associated on the cell surface. Anjuère F; Horvath C; Cerottini JC; Luescher IF Eur J Immunol; 1995 Jun; 25(6):1535-40. PubMed ID: 7614979 [TBL] [Abstract][Full Text] [Related]
7. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724 [TBL] [Abstract][Full Text] [Related]
8. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Lacabanne V; Viguier M; Guillet JG; Choppin J Eur J Immunol; 1996 Nov; 26(11):2635-9. PubMed ID: 8921949 [TBL] [Abstract][Full Text] [Related]
9. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells. Liu X; Peralta EA; Ellenhorn JD; Diamond DJ Cancer Res; 2000 Feb; 60(3):693-701. PubMed ID: 10676655 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Nikitina EY; Clark JI; Van Beynen J; Chada S; Virmani AK; Carbone DP; Gabrilovich DI Clin Cancer Res; 2001 Jan; 7(1):127-35. PubMed ID: 11205900 [TBL] [Abstract][Full Text] [Related]
11. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Houbiers JG; Nijman HW; van der Burg SH; Drijfhout JW; Kenemans P; van de Velde CJ; Brand A; Momburg F; Kast WM; Melief CJ Eur J Immunol; 1993 Sep; 23(9):2072-7. PubMed ID: 8370389 [TBL] [Abstract][Full Text] [Related]
12. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253 [TBL] [Abstract][Full Text] [Related]
13. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698 [TBL] [Abstract][Full Text] [Related]
14. Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Gnjatic S; Bressac-de Paillerets B; Guillet JG; Choppin J Eur J Immunol; 1995 Jun; 25(6):1638-42. PubMed ID: 7542198 [TBL] [Abstract][Full Text] [Related]
15. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. Yu Z; Liu X; McCarty TM; Diamond DJ; Ellenhorn JD J Surg Res; 1997 May; 69(2):337-43. PubMed ID: 9224403 [TBL] [Abstract][Full Text] [Related]
16. Immunization of retrovirus-transfected dendritic cells induces specific cytotoxic T lymphocytes for two distinct malarial peptides presented by Kd molecule. Hetttihewa LM Int Immunopharmacol; 2003 Oct; 3(10-11):1401-11. PubMed ID: 12946436 [TBL] [Abstract][Full Text] [Related]
17. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698 [TBL] [Abstract][Full Text] [Related]
18. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection. Tjoa BA; Kranz DM Cancer Res; 1994 Jan; 54(1):204-8. PubMed ID: 7505197 [TBL] [Abstract][Full Text] [Related]
19. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties. Bristol JA; Schlom J; Abrams SI J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787 [TBL] [Abstract][Full Text] [Related]
20. Epitope selection in major histocompatibility complex class I-mediated pathway is affected by the intracellular localization of an antigen. Yamazaki H; Tanaka M; Nagoya M; Fujimaki H; Sato K; Yago T; Nagata T; Minami M Eur J Immunol; 1997 Feb; 27(2):347-53. PubMed ID: 9045903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]